Mucins and isoforms thereof in diseases characterized by barrier dysfunction University of Antwerp
The present invention relates to the field of mucins and isoforms thereof, more in particular for use in the diagnosis, monitoring, prevention and/or treatment of a disease characterized by barrier dysfunction, such as but not limited to a gastrointestinal disorder (e.g. Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), cancer, gastro-intestinal infections, obesitas, non-alcoholic fatty liver disease (NAFLD)), neurodegenerative disorders, respiratory infections,... more in particular coronaviral infections In a specific embodiment, said mucins and/or isoforms thereof are ...